NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ
$6.95−$0.4500 (−6.08%) on the dayAs of the close; data may be delayed.
NRSN price, last 12 months
Key stats
- Previous close
- $7.40
- Open
- $7.18
- Day range
- $6.73 – $7.18
- 52-week range
- $5.00 – $26.64
- Volume
- 7K
- Avg volume (20 days)
- 26.8K
- Market cap
- $13.2M
Performance
1W+9.5%
1M−15.0%
3M−54.1%
6M−54.9%
YTD−54.8%
1Y−72.0%
vs S&P 500, 1Y−88.8 pts
Technicals and fundamentals
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
- Listed on
- NASDAQ
- Market cap
- $13.2M